Breaking News Instant updates and real-time market news.

NERV

Minerva

$4.60

-0.16 (-3.36%)

08:00
11/04/19
11/04
08:00
11/04/19
08:00

Minerva expects seltorexant findings to help define Phase 3 clinical program

The company said, "During 2019, the Company completed and announced top-line results from three Phase 2b trials and one Phase 1b trial with seltorexant. Three of these trials were in MDD and one was in insomnia disorder. Key conclusions following data analyses from these trials include the following. Seltorexant shows clinically meaningful and consistent improvements in mood and sleep symptoms. In depressed patients, seltorexant shows improvement in mood as monotherapy and as add-on therapy to SSRIs or SNRIs, and its effect on mood is stronger in patients with insomnia. Among the doses of seltorexant tested, 20 mg shows the most robust and consistent effect on mood. In both adult and elderly subjects, seltorexant improves both sleep induction and sleep maintenance compared to zolpidem. Seltorexant shows a safety and tolerability profile similar to placebo. These findings are expected to help define a Phase 3 clinical development program for seltorexant that potentially will encompass both MDD and insomnia."

  • 12

    Nov

NERV Minerva
$4.60

-0.16 (-3.36%)

09/17/19
SBSH
09/17/19
NO CHANGE
SBSH
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list
Citi analyst Joel Beatty removed The Medicines Co. (MDCO) and Minerva (NERV) from his top five Buy-rated stocks in SMid cap Biotech. These stocks are up 34% and 28%, respectively, since the analyst established them as among his top five Buy-rated stocks in July. Beatty replaced The Medicines Co. and Minerva with Amarin (AMRN) and Sarepta Therapeutics (SRPT). His top five buys are now Amarin, Eloxx Pharmaceuticals (ELOX), NGM Biopharmaceuticals (NGM), PTC Therapeutics (PTCT) and Sarepta. He wants to own Amarin into the November FDA panelmeeting, believing it will be "innocuous" and lead to a risk reduction label for Vascepa. On Sarepta, Beatty thinks the recent share pullback is overblown, and he reiterates his thesis that "although there will likely be some minor bumps on the road," the company will ultimately win the Image result for Duchenne muscular dystrophy gene therapy race
09/18/19
WBLR
09/18/19
INITIATION
WBLR
Outperform
Minerva initiated with an Outperform at William Blair
William Blair analyst Myles Minter started Minerva Neurosciences, a clinical-stage biopharmaceutical company developing therapies for mood disorders and central nervous system diseases, with an Outperform rating and $26 fair value estimate. The company has four pipeline assets, three of which are in late-stage clinical development, Minter tells investors in a research note. The analyst is confident in the patient screening process and risk/benefit profile of roluperidone as potentially the first FDA-approved therapy to treat negative symptoms of schizophrenia.
09/25/19
CHDN
09/25/19
INITIATION
Target $17
CHDN
Buy
Minerva initiated with a Buy at Chardan
Chardan started Minerva Neurosciences with a Buy rating and $17 price target.
10/02/19
HCWC
10/02/19
NO CHANGE
Target $22
HCWC
Buy
Minerva investors 'missing the forest for the trees,' says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao is not that surprised that shares of Minerva Neurosciences came under pressure yesterday after the company disclosed a cyber-attack on a vendor delayed completion of enrollment for roluperidone and that the Phase 3 trial is now expected to readout in the first half of 2020. However, another "strong data set for seltorexant should have been enough to carry the day," Tsao tells investors in a research note partially titled "Missing the Forest for the Trees as Seltorexant Shines Again." While the data released by the company was not powered for statistical significance, it added "another impressive piece to the body of evidence supporting its utility," contends the analyst. Further, Tsao says that while pushing back roluperidone's readout is a disappointment, the news "doesn't fundamentally change things" since Minerva is capitalized into mid-2021 and the drug's new drug application submission has not been meaningfully impacted. The analyst reiterates a Buy rating on Minerva with a $22 price target.

TODAY'S FREE FLY STORIES

07:55
12/10/19
12/10
07:55
12/10/19
07:55
Conference/Events
FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting »

The Committee discusses…

THS

TreeHouse

$51.68

0.16 (0.31%)

07:55
12/10/19
12/10
07:55
12/10/19
07:55
Conference/Events
TreeHouse to host investor meeting »

Investor breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

ALB

Albemarle

$64.71

0.405 (0.63%)

07:54
12/10/19
12/10
07:54
12/10/19
07:54
Conference/Events
Albemarle to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DVN

Devon Energy

$23.15

-0.005 (-0.02%)

, HES

Hess Corp.

$61.75

-0.505 (-0.81%)

07:54
12/10/19
12/10
07:54
12/10/19
07:54
Recommendations
Devon Energy, Hess Corp., Vermilion Energy, Concho Resources, EOG Resources, Diamondback Energy, Parsley Energy, Pioneer Natural, WPX Energy analyst commentary  »

JPMorgan upgrades Devon…

DVN

Devon Energy

$23.15

-0.005 (-0.02%)

HES

Hess Corp.

$61.75

-0.505 (-0.81%)

VET

Vermilion Energy

$14.89

0.13 (0.88%)

CXO

Concho Resources

$76.50

0.01 (0.01%)

EOG

EOG Resources

$74.51

0.52 (0.70%)

FANG

Diamondback Energy

$83.79

0.56 (0.67%)

PE

Parsley Energy

$16.25

0.03 (0.18%)

PXD

Pioneer Natural

$133.20

-0.71 (-0.53%)

WPX

WPX Energy

$10.57

0.06 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMRX

Chimerix

$2.54

0.07 (2.83%)

07:51
12/10/19
12/10
07:51
12/10/19
07:51
Hot Stocks
Chimerix presents DSTAT program data at ASH »

Chimerix announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$55.79

-0.36 (-0.64%)

07:51
12/10/19
12/10
07:51
12/10/19
07:51
Conference/Events
Delta Air Lines to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

FTSV

Forty Seven

$30.44

16.04 (111.39%)

07:49
12/10/19
12/10
07:49
12/10/19
07:49
Recommendations
Forty Seven analyst commentary  »

Forty Seven price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKU

BankUnited

$35.53

0.07 (0.20%)

07:48
12/10/19
12/10
07:48
12/10/19
07:48
Initiation
BankUnited initiated  »

BankUnited initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXGN

NextGen Healthcare

$18.15

0.24 (1.34%)

07:48
12/10/19
12/10
07:48
12/10/19
07:48
Conference/Events
NextGen Healthcare to host analyst day »

Analyst day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CG

Carlyle Group

$29.17

-0.36 (-1.22%)

07:46
12/10/19
12/10
07:46
12/10/19
07:46
Initiation
Carlyle Group initiated  »

Carlyle Group reinstated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MET

MetLife

$49.57

0.065 (0.13%)

07:45
12/10/19
12/10
07:45
12/10/19
07:45
Conference/Events
MetLife to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RDFN

Redfin

$20.77

-0.46 (-2.17%)

07:45
12/10/19
12/10
07:45
12/10/19
07:45
Upgrade
Redfin rating change  »

Redfin upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$61.32

1.38 (2.30%)

07:44
12/10/19
12/10
07:44
12/10/19
07:44
Hot Stocks
Bristol-Myers presents OS, safety data from pivotal CC-486 study QUAZAR AML-001 »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CONN

Conn's

$20.51

1.08 (5.56%)

07:43
12/10/19
12/10
07:43
12/10/19
07:43
Downgrade
Conn's rating change  »

Conn's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

LULU

Lululemon

$231.08

1.58 (0.69%)

07:42
12/10/19
12/10
07:42
12/10/19
07:42
Recommendations
Lululemon analyst commentary  »

Lululemon price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

GOLD

Barrick Gold

$16.85

-0.045 (-0.27%)

07:41
12/10/19
12/10
07:41
12/10/19
07:41
Hot Stocks
Barrick Gold to sell 90% interest in Massawa project to Teranga for up to $430M »

Barrick Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$62.68

-1.77 (-2.75%)

07:41
12/10/19
12/10
07:41
12/10/19
07:41
Hot Stocks
Sage Therapeutics announces planned progression of SAGE-718 »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$237.33

-4.62 (-1.91%)

07:40
12/10/19
12/10
07:40
12/10/19
07:40
Recommendations
RH analyst commentary  »

RH price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCC

Wesco

$54.92

-0.32 (-0.58%)

, AXE

Anixter

$88.88

-0.18 (-0.20%)

07:39
12/10/19
12/10
07:39
12/10/19
07:39
Upgrade
Wesco, Anixter rating change  »

Wesco upgraded to Strong…

WCC

Wesco

$54.92

-0.32 (-0.58%)

AXE

Anixter

$88.88

-0.18 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

NFLX

Netflix

$302.48

-4.88 (-1.59%)

07:39
12/10/19
12/10
07:39
12/10/19
07:39
Conference/Events
Netflix management to meet with UBS »

Dinner Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 10

    Dec

SGEN

Seattle Genetics

$114.26

-3.26 (-2.77%)

07:38
12/10/19
12/10
07:38
12/10/19
07:38
Initiation
Seattle Genetics initiated  »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

SYBT

S.Y. Bancorp

$41.02

-0.03 (-0.07%)

07:38
12/10/19
12/10
07:38
12/10/19
07:38
Conference/Events
S.Y. Bancorp management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

DG

Dollar General

$154.81

0.075 (0.05%)

07:37
12/10/19
12/10
07:37
12/10/19
07:37
Hot Stocks
Dollar General announces availability of CBD products in select states »

Dollar General announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HROW

Harrow Health

$6.53

0.04 (0.62%)

07:37
12/10/19
12/10
07:37
12/10/19
07:37
Hot Stocks
Harrow Health subsidiary announces outsourcing facility ships to California »

ImprimisRx, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TENB

Tenable Holdings

$24.81

-0.46 (-1.82%)

07:36
12/10/19
12/10
07:36
12/10/19
07:36
Recommendations
Tenable Holdings analyst commentary  »

Tenable Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.